Waters Corporation logo
Waters Corporation (WAT)
Compare

Waters Corporation (WAT) EBITDA Margin: 31.97%

Is Waters Corporation’s EBITDA margin high or low?

Waters Corporation's EBITDA margin of 31.97% is in line with its 5-year average of 33.93%, near the low end of its 5-year range (31.97%–35.28%).

The EBITDA margin for Waters Corporation (WAT) is 31.97% as of Wednesday, June 10, 2026. It is below its 12-month average by 4.57% (33.50%).

WAT EBITDA Margin Chart

WAT EBITDA Margin
31.97%-8.74% 1Y
Zoom

WAT Average EBITDA Margin Chart

WAT Current vs Average EBITDA Margin Chart

WAT EBITDA Margin Metrics

EBITDA MARGIN

31.97%

EBITDA MARGIN AVG TTM

33.50%

EBITDA MARGIN AVG 3Y

33.77%

EBITDA MARGIN AVG 5Y

33.93%

EBITDA MARGIN AVG 10Y

34.05%

EBITDA MARGIN AVG 15Y

33.28%

EBITDA MARGIN AVG 20Y

32.19%

CURRENT VS TTM AVG

-4.57%

CURRENT VS 3Y AVG

-5.33%

CURRENT VS 5Y AVG

-5.77%

CURRENT VS 10Y AVG

-6.11%

CURRENT VS 15Y AVG

-3.94%

CURRENT VS 20Y AVG

-0.67%

WAT Competitors' EBITDA Margin

NAMEMARKET CAPEBITDA MARGINTTM3Y5Y
Waters Corporation (WAT)31.97%33.50%33.77%33.93%
Mettler-Toledo International Inc. (MTD)$22.85B30.67%31.14%31.31%30.59%
BioNTech SE (BNTX)$21.81B-9.29%-11.31%22.27%24.39%
Veeva Systems Inc. (VEEV)$26.73B28.68%27.64%24.37%25.68%
Biogen Inc. (BIIB)$29.00B31.60%31.28%30.38%32.54%
DexCom, Inc. (DXCM)$29.24B24.96%24.20%23.29%21.36%
Moderna, Inc. (MRNA)$18.40B-131.33%-118.72%-58.41%-40.82%
IQVIA Holdings Inc. (IQV)$30.60B21.24%21.82%21.39%20.63%
Hologic, Inc. (HOLX)$16.97B24.97%28.56%32.04%36.42%
Centene Corporation (CNC)$31.94B-2.64%0.58%1.90%2.49%

Margin Comparison

Gross Margin

55.0%

EBITDA Margin

32.0%

Operating Margin

17.1%

Net Margin

11.9%

Formula: EBITDA Margin = (EBITDA / Revenue) × 100

Why EBITDA Margin matters:

  • Removes effects of depreciation policies (D&A)
  • Capital structure neutral (ignores interest)
  • Tax neutral (ignores tax differences)
  • Good proxy for operating cash generation

Waters Corporation EBITDA Margin Formula & Definition

EBITDA Margin = EBITDA / Revenue

EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Waters Corporation EBITDA Margin FAQ

What is the EBITDA margin for Waters Corporation (WAT)?
The EBITDA margin for WAT stock is 31.97%.
Is Waters Corporation's EBITDA margin high or low?
Waters Corporation's EBITDA margin of 31.97% is in line with its 5-year average of 33.93%, near the low end of its 5-year range (31.97%–35.28%).
What is the TTM average EBITDA margin for Waters Corporation (WAT)?
The TTM average EBITDA margin for WAT stock is 33.50%.
What is the 3Y average EBITDA margin for Waters Corporation (WAT)?
The 3Y average EBITDA margin for WAT stock is 33.77%.
What is the 5Y average EBITDA margin for Waters Corporation (WAT)?
The 5Y average EBITDA margin for WAT stock is 33.93%.
What is the 10Y average EBITDA margin for Waters Corporation (WAT)?
The 10Y average EBITDA margin for WAT stock is 34.05%.
What is the 15Y average EBITDA margin for Waters Corporation (WAT)?
The 15Y average EBITDA margin for WAT stock is 33.28%.
What is the 20Y average EBITDA margin for Waters Corporation (WAT)?
The 20Y average EBITDA margin for WAT stock is 32.19%.

Waters Corporation EBITDA Margin History

DATEEBITDA MARGIN
2025-12-3131.97%
2024-12-3135.03%
2023-12-3133.86%
2022-12-3134.22%
2021-12-3135.28%
2020-12-3133.20%
2019-12-3134.58%
2018-12-3134.68%
2017-12-3134.82%
2016-12-3134.21%
2015-12-3132.72%
2014-12-3131.12%
2013-12-3131.50%
2012-12-3131.71%
2011-12-3132.28%
2010-12-3131.30%
2009-12-3130.35%
2008-12-3130.22%
2007-12-3127.30%
2006-12-3127.32%
2005-12-3128.22%
2004-12-3129.58%
2003-12-3126.50%
2002-12-3127.08%
2001-12-3121.35%
2000-12-3130.22%
1999-12-3129.26%
1998-12-3126.63%
1997-12-3112.61%
1996-12-3122.53%

About Waters Corporation

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

Milford, MA
7,600 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Udit Batra